Zacks Investment Research on MSN
ALT stock up 17% after pemvidutide gets FDA breakthrough tag for MASH
Altimmune ALT announced that the FDA has granted Breakthrough Therapy Designation to its lead pipeline candidate, pemvidutide ...
The key opportunities in the MASH treatment market include focusing on the drug segment, especially FGF21-based therapies, ...
Fatty liver disease happens when too much fat builds up in the liver. Metabolic dysfunction-associated steatohepatitis (MASH) is a severe type of fatty liver disease where fat buildup causes liver ...
What Are Clinical Trials for MASH? Clinical trials for MASH are research studies that evaluate potential new treatments for a form of liver disease called metabolic dysfunction-associated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback